By Hendra Lukman 
Researchers have identified a significant advancement in the management of chronic myeloid leukemia (CML) with the development of a highly sensitive and accurate digital polymerase chain reaction (dPCR) assay for the BCR::ABL1 fusion transcript. This novel application of dPCR demonstrates the ability to reliably quantify stable deep molecular remission, a critical benchmark for determining which patients might be candidates for discontinuing lifelong drug treatment. The findings, published in The Journal of Molecular Diagnostics by Elsevier, indicate that this new method surpasses the sensitivity of the current standard, real-time quantitative PCR (RT-qPCR), in detecting the ultralow levels of residual leukemic disease that are indicative of profound remission. This breakthrough holds substantial promise for improving treatment strategies and potentially offering patients a chance at treatment-free remission.
A New Era in CML Monitoring: The Power of Digital PCR
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome, a specific chromosomal abnormality resulting from a reciprocal translocation between chromosomes 9 and 22. This translocation creates a fusion gene, BCR::ABL1, which encodes a constitutively active tyrosine kinase. This aberrant kinase drives the uncontrolled proliferation of myeloid cells, leading to the hallmark features of CML. For decades, the advent of tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, and nilotinib, has revolutionized CML treatment, transforming a once fatal disease into a manageable chronic condition for most patients. These targeted therapies effectively inhibit the BCR::ABL1 kinase, suppressing leukemic cell growth and inducing molecular remissions.
A significant goal in modern CML management is achieving "deep molecular remission," defined by a substantial reduction in BCR::ABL1 transcript levels below a certain threshold. The most stringent level of remission is often referred to as MR5.0, which signifies the absence of detectable BCR::ABL1 transcripts down to a level of one copy in 100,000 normal cells, or a ratio of less than 0.001% on the International Scale (IS). For a subset of patients who achieve and maintain deep molecular remission for an extended period, discontinuing TKI therapy, known as treatment-free remission (TFR), is a viable option. This possibility offers patients freedom from daily medication, potential reduction of long-term side effects, and an improved quality of life. However, the successful selection of patients for TKI discontinuation hinges on the ability to accurately and reliably detect extremely low levels of residual disease. If residual leukemic cells persist, they can proliferate and lead to molecular relapse.
The Limitations of Current Standard and the Emergence of dPCR
The current gold standard for monitoring BCR::ABL1 levels in CML patients is RT-qPCR. While effective for quantifying higher levels of transcripts, RT-qPCR has inherent limitations when it comes to detecting the vanishingly small amounts of residual disease present in deep molecular remission. Its sensitivity is often limited by the dynamic range of the assay and the presence of background noise, making it challenging to reliably distinguish between true absence of disease and levels below its limit of detection. This ambiguity can create uncertainty in clinical decision-making regarding TKI discontinuation.
The study, led by Peter E. Westerweel, MD, PhD, from the Department of Internal Medicine at Albert Schweitzer Hospital in Dordrecht, The Netherlands, investigated the utility of BCR::ABL1 digital PCR as a superior alternative for quantifying deep molecular remission. Digital PCR is a highly precise method that partitions a DNA sample into thousands to millions of individual reactions, or "droplets." Each droplet can either contain a target molecule or not. By counting the number of positive droplets, dPCR can provide an absolute quantification of target molecules without relying on a standard curve, leading to enhanced accuracy and sensitivity, especially at very low target concentrations.
Unveiling the Findings: Superior Sensitivity and Accuracy
The nationwide prospective multicenter study collected samples from Dutch CML patients who were being considered for a TKI discontinuation attempt. The study enrolled 136 patients across 31 medical centers, with a total of 168 samples collected between July 2020 and May 2023. The primary objective was to evaluate the performance of BCR::ABL1 dPCR in accurately quantifying BCR::ABL1 transcripts at levels relevant for predicting treatment-free remission.
"In our research, we show that digital PCR for BCR::ABL reaches a sufficiently high sensitivity in almost all (97%) samples of patients in deep molecular remission," stated Dr. Westerweel. "The molecular target was detected in two thirds of patients that were below the limit of detection of standard RT-qPCR technique. Digital PCR was therefore more sensitive and more accurate, allowing a reliable measurement to select CML patients in deep remission eligible for drug treatment discontinuation."
The study reported that BCR::ABL1 dPCR accurately quantified the transcript levels around 0.0023% on the International Scale, which is a clinically significant threshold for predicting treatment-free remission. The assay’s target sensitivity was set at MR5.0, requiring the reliable detection of just one BCR::ABL1 transcript in a background of at least 100,000 normal copies. This stringent sensitivity was achieved in an impressive 97% of assessments. Critically, dPCR was able to detect and quantify the BCR::ABL1 construct in 68% of samples that were below the limit of detection of the standard RT-qPCR assay. This finding underscores the significant gap in sensitivity between the two techniques and highlights the potential of dPCR to identify patients with a higher likelihood of sustained remission.
A Novel Insight: Transcript Type Identification
Beyond its superior sensitivity in quantifying BCR::ABL1 transcripts, the dPCR assay revealed an additional valuable capability: the identification of different BCR::ABL1 transcript types. The BCR::ABL1 fusion can arise from different breakpoints within the BCR gene, most commonly resulting in either the e13a2 or e14a2 transcript types. While this information is crucial for understanding CML biology and prognosis, it can be difficult to ascertain using standard techniques once patients achieve deep molecular remission.
The researchers observed variations in the fluorescence levels of droplets generated by the dPCR technique, which correlated with different transcript types. "Some patients have a so-called e13a2 transcript type, while others have an e14a2 transcript type," explained Dr. Westerweel. "We validated that the assay can be used to identify the transcript type in patients with detectable disease. This additional discovery is very relevant as we have previously shown that the transcript type is a risk factor for molecular relapse after drug discontinuation. Often, the transcript type is not known for patients and cannot be established using standard techniques once patients are in deep remission."
Previous research has indicated that patients with the e13a2 transcript type may have a higher risk of molecular relapse after discontinuing TKIs compared to those with the e14a2 type. The ability of dPCR to identify the transcript type in a sensitive manner, even in patients with very low levels of residual disease, offers a significant advantage for personalized risk assessment. This information can help clinicians refine their selection of patients for TKI discontinuation and potentially tailor follow-up strategies.
Towards Wider Clinical Adoption and Implications for Patient Care
The BCR::ABL1 digital PCR assay used in this study is based on an FDA-approved, commercially available kit. This factor is crucial for its feasibility for widespread clinical adoption. The availability of a standardized and validated assay reduces barriers to implementation in routine diagnostic laboratories.
The implications of this research are far-reaching for the management of CML. By providing a more precise and sensitive method for monitoring minimal residual disease, BCR::ABL1 dPCR can:
- Improve Patient Selection for TKI Discontinuation: More accurately identify patients who have achieved a level of remission deep enough to safely attempt TKI discontinuation, thereby increasing the success rate of TFR attempts and reducing the risk of relapse.
- Enhance Risk Stratification: The ability to identify transcript types alongside sensitive quantification of BCR::ABL1 allows for a more nuanced assessment of relapse risk, enabling personalized treatment decisions.
- Optimize Treatment Monitoring: Provide earlier detection of potential molecular relapse, allowing for timely intervention and reinitiation of therapy to maintain remission.
- Reduce Patient Burden: Potentially decrease the duration of TKI therapy for eligible patients, mitigating long-term side effects and improving quality of life.
"Digital PCR for BCR::ABL is a valuable and reliable tool to aid clinical decision making in CML," concluded Dr. Westerweel.
Future Directions and Broader Impact
While the current study focused on the application of dPCR for BCR::ABL1 quantification, the principles and technology behind digital PCR have broader implications for cancer diagnostics and monitoring. Its high sensitivity and absolute quantification capabilities make it suitable for detecting and monitoring other oncogenic fusion genes, circulating tumor DNA, and gene expression changes at very low levels.
The findings from this study represent a significant step forward in the quest for optimizing CML treatment strategies. By providing clinicians with a more powerful tool to assess the depth of molecular remission, BCR::ABL1 digital PCR has the potential to expand the number of patients who can safely consider treatment-free remission, offering them a life free from daily medication and its associated burdens. Further research may explore the long-term outcomes of patients selected for TKI discontinuation based on dPCR results and investigate the potential for using dPCR in other hematological malignancies. The integration of such advanced molecular diagnostic tools into routine clinical practice is crucial for advancing personalized medicine and improving patient outcomes in oncology.